Overview

HAI Irinotecan + IV Bevacizumab, Bevacizumab & Oxaliplatin or Bevacizumab & Cetuximab in Advanced Cancers Metastatic to Liver

Status:
Completed

Trial end date:
2015-08-01

Target enrollment:

Participant gender:

Summary

The goal of this clinical research study is to learn the highest tolerable dose of irinotecan that can be given directly into the liver, in combination with other drugs given by vein. The other drug combinations given by vein include bevacizumab alone, bevacizumab plus oxaliplatin, and bevacizumab plus cetuximab. This will be tested in patients with advanced solid tumors that have spread to the liver. The safety of these drug combinations will also be studied.

Phase:

Phase 1

Details

Lead Sponsor:

M.D. Anderson Cancer Center

Treatments:

Bevacizumab
Camptothecin
Cetuximab
Irinotecan
Oxaliplatin